Published in Nat Chem Biol on October 27, 2013
Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med (2015) 1.98
Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell (2016) 1.91
Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell (2015) 1.55
Modulating the stem cell niche for tissue regeneration. Nat Biotechnol (2014) 1.28
A hostel for the hostile: the bone marrow niche in hematologic neoplasms. Haematologica (2015) 0.99
Role of Microenvironment in Resistance to Therapy in AML. Curr Hematol Malig Rep (2015) 0.92
Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nat Protoc (2016) 0.88
Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion. Sci Rep (2014) 0.85
Evolving concepts of tumor heterogeneity. Cell Biosci (2014) 0.84
The cell biology of late blight disease. Curr Opin Microbiol (2016) 0.84
A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia. Blood Cancer J (2014) 0.83
Leukaemia 'firsts' in cancer research and treatment. Nat Rev Cancer (2016) 0.79
Quantifying co-cultured cell phenotypes in high-throughput using pixel-based classification. Methods (2015) 0.79
Advances in discovering small molecules to probe protein function in a systems context. Curr Opin Chem Biol (2015) 0.78
Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis. Bioinformatics (2014) 0.78
Harnessing the apoptotic programs in cancer stem-like cells. EMBO Rep (2015) 0.77
Tumour microenvironment: Destroying leukaemia stem cell habitats. Nat Rev Cancer (2013) 0.76
2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent. PLoS One (2015) 0.76
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood (2017) 0.75
High-Throughput, Automated Image Processing for Large-Scale Fluorescence Microscopy Experiments. Microsc Microanal (2016) 0.75
Targeting leukemia stem cells: in vitro veritas? Oncotarget (2014) 0.75
High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells. J Clin Invest (2016) 0.75
Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs. Bioorg Med Chem (2016) 0.75
Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. Oncotarget (2016) 0.75
Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat Chem (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol (2006) 32.51
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell (2009) 12.96
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Statin use and reduced cancer-related mortality. N Engl J Med (2012) 8.51
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell (2006) 6.34
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell (2004) 5.98
Target-oriented and diversity-oriented organic synthesis in drug discovery. Science (2000) 5.72
Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc Natl Acad Sci U S A (2009) 5.15
Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature (2009) 4.14
Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell (2012) 4.13
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood (2001) 3.90
An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell (1996) 3.60
The anthracyclines: will we ever find a better doxorubicin? Semin Oncol (1992) 3.28
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood (2005) 3.22
K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem (1997) 3.21
Targeting protein prenylation for cancer therapy. Nat Rev Cancer (2011) 2.60
Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation (2004) 2.49
Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood (2008) 2.26
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood (2007) 2.14
In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat Genet (2009) 1.99
Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res (2000) 1.94
Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol (1996) 1.90
Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood (2002) 1.62
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat Chem Biol (2009) 1.58
OP9 mouse stromal cells rapidly differentiate into adipocytes: characterization of a useful new model of adipogenesis. J Lipid Res (2005) 1.58
Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem (1997) 1.57
Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res (2001) 1.46
Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev (2011) 1.44
Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs (1993) 1.41
Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood (2003) 1.40
Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat (2009) 1.34
Statins and cancer: current and future prospects. Cancer Lett (2012) 1.27
Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia (1994) 1.25
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood (1999) 1.24
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood (2007) 1.18
Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp Hematol (2007) 1.02
Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood (2012) 0.94
The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression. Cell Cycle (2009) 0.90
Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy. Trends Pharmacol Sci (2006) 0.88
Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells. Leukemia (2011) 0.87
Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemia. Blood (1996) 0.83
The toxicity of cytarabine. Drug Saf (1990) 0.82
FLT3 signaling and the development of inhibitors that target FLT3 kinase activity. Crit Rev Oncog (2012) 0.80
Ubiquitin Ligase TRIM62 Regulates CARD9-Mediated Anti-fungal Immunity and Intestinal Inflammation. Immunity (2015) 0.84
Selective Chemical Inhibition of PGC-1α Gluconeogenic Activity Ameliorates Type 2 Diabetes. Cell (2017) 0.75
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell (2017) 0.75